Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL165745 | 1.00 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1HSD17B10HIF1ACYP1B1 | |
| Quinoline SCHEMBL28210108 | 0.84 | ALDH1A1 (0.57) | L3MBTL1ALDH1A1HSD17B10CYP1A2PDE4A | |
| Isoquinoline SCHEMBL28149933 | 0.82 | KDM4E (0.42) | L3MBTL1CYP1A2MAPTLMNACYP3A4 | |
| SCHEMBL374938 | 0.77 | ALDH1A1 (0.39) | L3MBTL1ALDH1A1HSD17B10HIF1ACYP1B1 | |
| SCHEMBL29091622 | 0.77 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1HSD17B10HIF1ACYP1B1 | |
| SCHEMBL23860797 | 0.77 | F12 (0.47) | L3MBTL1ALDH1A1HSD17B10HIF1ACYP1B1 | |
| SCHEMBL2170888 | 0.77 | CYP2A6 (0.47) | L3MBTL1ALDH1A1HSD17B10HIF1ACYP1B1 | |
| SCHEMBL30544379 | 0.77 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1HSD17B10HIF1ACYP1B1 | |
| SCHEMBL7882102 | 0.77 | TRPM4 (0.45) | L3MBTL1ALDH1A1HSD17B10HIF1ACYP1B1 | |
| SCHEMBL3083764 | 0.77 | TRPM4 (0.45) | L3MBTL1ALDH1A1HSD17B10HIF1ACYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649232-B2 | Synthetic dimeric cinchona alkaloids against cancer | Ares Pharmaceuticals, LLC (US) | 2023-05-16 | — | — | US | claimed |
| US-20220372029-A1 | SYNTHETIC DIMERIC CINCHONA ALKALOIDS AGAINST CANCER | Ares Pharmaceuticals, LLC (US) | 2022-11-24 | — | — | US | claimed |
| CN-122094947-A | PARP1 inhibitor compounds | — | 2026-05-26 | — | — | CN | disclosed |
| CN-119060060-A | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-115605466-B | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| CN-110913855-B | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-117659050-A | Quinazoline heterocyclic derivatives as KRAS mutation inhibitors for the treatment of cancer | 深圳福沃药业有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2023-12-21 | — | — | US | disclosed |
| CN-116925100-A | Substituted thiophenoquinolinone compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-11649232-B2 | Synthetic dimeric cinchona alkaloids against cancer | Ares Pharmaceuticals, LLC (US) | 2023-05-16 | — | — | US | disclosed |
| CN-115605466-A | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司（US） | 2023-01-13 | — | — | CN | disclosed |
| US-20220372029-A1 | SYNTHETIC DIMERIC CINCHONA ALKALOIDS AGAINST CANCER | Ares Pharmaceuticals, LLC (US) | 2022-11-24 | — | — | US | disclosed |
| CN-114369096-A | Triheterocyclic derivatives, pharmaceutical compositions and uses thereof | 上海迪诺医药科技有限公司 | 2022-04-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | L3MBTL1 4448/4885ALDH1A1 1457/4885HSD17B10 2539/4885 |
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | L3MBTL1 4021/4885ALDH1A1 1320/4885HSD17B10 1483/4885 |
| US-11649232-B2 | Synthetic dimeric cinchona alkaloids against cancer | BAD, MCL1, BCL9 | L3MBTL1 463/4885ALDH1A1 1167/4885HSD17B10 1040/4885 |
| US-20220372029-A1 | SYNTHETIC DIMERIC CINCHONA ALKALOIDS AGAINST CANCER | BAD, MCL1, BCL9 | L3MBTL1 463/4885ALDH1A1 1167/4885HSD17B10 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.